[Parenteral iron and folic acid in patients on chronic hemodialysis: requirements, monitoring, and effective use].
Iron and folic acid metabolism were prospectively studied over a 7 year period in 12 patients on chronic hemodialysis. Three protocols of iron and folic acid administration were successively used: in Phase A (mean 35.5 months) iron dextran intravenously was used at high dose (mean 416 mg monthly) with folic acid 1 mg/day; in Phase B (mean 8.1 months) iron and folic acid were not given, and in Phase C low dose iron dextran (mean of 10 mg monthly) and folic acid 3 mg per week were administered. No other medications, except for blood transfusion or Aluminum hydroxide were used throughout. A good correlation was found between serum ferritin levels and bone marrow iron stores. No side effects of iron administration were noted. A significant rise in Hb levels was observed (9.21 g/dl in Phase A to 10.3 g/dl in Phase C). Red cell protoporphyrin levels remained normal. With folic acid supplement of 3 mg per week, serum folate level remained within normal limits.
Duclos
J
J
Depto de Nefrología, Hospital Naval de Valparaíso, Chile.
D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D005293:Ferritins / Q000097:blood; D005492:Folic Acid / Q000008:administration & dosage* / Q000378:metabolism; D005921:Glomerulonephritis / Q000097:blood / Q000628:therapy*; D006403:Hematologic Tests; D006801:Humans; D007263:Infusions, Parenteral; D007501:Iron / Q000008:administration & dosage* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D006435:Renal Dialysis / Q000379:methods*
D005293:Ferritins; D005492:Folic Acid; D007501:Iron
Hierro parenteral y ácido fólico en pacientes en hemodiálisis, crónica: requerimientos, monitorización y utilización efectiva.